Publication Topic

Finley BL, Benson SM, Marsh GM. 2017. Cosmetic talc as a risk factor for pleural mesothelioma: A weight of evidence valuation of the epidemiology. Inhal Toxicol 29(4):179–185.

Finley BL, Scott PK, Burns AM, Marsh GM. Does PCB exposure cause non-Hodgkins lymphoma? A weight of evidence evaluation. Late-breaking poster presentation at Society of Toxicology 56^th Annual Meeting, Baltimore, MD, 2017.

Finley BL, Donovan ED, Kovochich M, Paustenbach DJ, Urban AM. Perineal use of cosmetic talc as a risk factor for ovarian cancer: A weight-of-evidence evaluation. Abstract #1288. Poster presentation at Society of Toxicology 56^th Annual Meeting, Baltimore, MD, 2017.

Cui Y, Li J, Weng L, Wirbisky SE, Freeman JL, Liu J, Liu Q, Yuan X, Irudayaraj J. 2016. Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget 7(49):81698–81714; doi: 10.18632/oncotarget.13173.

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, … Kelsh MA, et al. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8–26.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181. doi: 10.1007/s12029-016-9809-5.

Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA, Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4:1 http://dx.doi.org/10.4172/2329-6917.1000208

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7): 500–503.

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M, et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 101(12):1524–1533. doi: 10.3324/haematol.2016.144311.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

Panko JM, Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

Pierce JS, Ruestow PS, Finley BL. An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Poster presentation at American Industrial Hygiene Conference & Exposition (AIHce), 2016.

Suh M, Thompson CM, Brorby GP, Mittal L, Proctor DM. 2016. Inhalation cancer risk assessment of cobalt metal. Regul Toxicol Pharm 79(Aug):74-82; doi: 10.1016/j.yrtph.2016.05.009.

Pierce JS, Ruestow PS, Finley BL. An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Abstract #2139. Poster presentation at Society of Toxicology 55^th Annual Meeting, New Orleans, LA, 2016.

Benson SM, Batdorf S, Hitchcock KM, Galbraith DA, Finley BL. Asbestos exposure and pharyngeal and laryngeal cancer risk: A fiber-type specific meta-analysis. Abstract #2974. Poster presentation at Society of Toxicology 55^th Annual Meeting, New Orleans, LA, 2016.